digital health


It’s the Social Factors, Stupid! Lisa Suennen on Healthcare, Her Career, Digital Health Investing, and . . . Just Being Herself

She's been a highly sought after venture funder and knowledge broker in the field of digital health. STAT News wrote that upwards of 1,500 pitches crossed her desk last year at GE Ventures. But as of a couple weeks ago, it's a desk at which she's no longer sitting. So what's she up to next?

No, we did not get a scoop here, though we do feel important. This interview was scheduled long before the healthcare venture capitalist, podcaster, blogger extraordinaire made her big break recently with GE. And in fact we’ve always known her for her own brand that goes beyond any employer, that of Lisa Suennen.

Cutting through the Hype in Healthcare Innovation with David Shaywitz and Lisa Suennen

In today’s special studio interview, the health tech duo, David Shaywitz and Lisa Suennen, walk us through the changing paradigms around healthcare. They offer their thoughts on some of the new digital health and peer-to-peer social platforms which are becoming integrated in daily clinical care.

Lisa grew up in Silicon Valley and is an investor in the health tech space. David is a newcomer to the Valley and is currently the Chief Medical Officer at DNAnexus, a company that provides cloud based genomics data storage and analytics. They are both avid bloggers and recently compiled much of their written work together into a book, "TechTonics: Can Passionate Entrepreneurs Heal Healthcare with Technology?" They also co-host a new podcast by the same name.

An Industrial Revolution of Digital Healthcare: Interview with Sultan Meghji

Guest:

Sultan Meghji, Founder, Reformation Medicine

Bio and Contact Info

Listen (4:20) The end of technology as a specialty

Listen (4:12) Sequencing devices still a bottleneck for clinical genomics

Listen (4:39) How to become a bioinformatician in six months

Listen (4:39) Basic scientists vs. technicians

Listen (8:19) Going through the Industrial Revolution of digital health

Listen (5:05) Do you think about bioethics?

Listen (4:49) Yes to regulation, and yes to access for everyone

Data scientists like Sultan Meghji are a highly valued species in today's world. Beginning his career at the National Center for Supercomputing Applications (NCSA) where he worked on original internet technologies, Sultan has used his expertise in several industries, including finance, air transportation, and now biotechnology.

We've had Sultan on for a couple shows already, and his broad experience and far reaching vision made him an obvious choice for our series, The Bioinformatician Bottleneck.

"We could graduate ten times what we're graduating every year for a decade, and I still wouldn't be convinced that we have enough [bioinformaticians]," he says in today's interview.

What to do about it? Sultan has suggestions, one of which is to have a "Khan Academy style program for How to Become a Bioinformatician in 6 Months." What about the years it takes to train great basic scientists in an age when biologists are already being called "mere technicians?" Sultan says technicians can handle much of the work of commercializing research.

Sultan goes on to suggest there are other important bottlenecks, including the sequencing tools space. Does he stop to think about bioethics? And is he for or against FDA regulation of personal genomic information? Today's show is far reaching and centered around Sultan's goal of bringing genomics to the masses.

"It's almost like the Industrial Revolution of digital healthcare," he says. "We're going to call it something else, but . . .at some point my blood, or some part of me, is going to go into a diagnostic black box, and out is going to come some recommendation that a doctor didn't actually look at. And I'm going to take it to the bank."

Podcast brought to you by: Roswell Park Cancer Insititute, dedicated to understanding, preventing and curing cancer for over 115 years.

Moving to an "Outcomes" World with Steve Burrill

Podcast brought to you by: BioConference Live's annual Clinical Diagnostics Conference, May 29-31

Guests:

Steve Burrill, CEO, Burrill and Co Bio and Contact Info

Listen (4:38) Burrill and Buck Conference on Aging

Listen (7:32) Moving to a world in healthcare where we will pay for outcomes

Listen (6:23) Has it not always been about values?

Listen (4:24) Can Pharma create value outside of providing drugs?

Listen (1:08) Thoughts on gene patent case

"This is not your grandfather’s Buick anymore. If you grew up in biotech any time prior to the last five years, you need to reexamine your assumptions about the world of reimbursement." Ron Cohen, CEO, Acorda

This quote is taken from the yearly state of the industry book put out by Burrill and Company. CEO, Steve Burrill joins us today to discuss the newly published book this year subtitled, "Capturing Value." Cohen's quote summarizes the message in the book in which Burrill and his team argue persuasively that things in healthcare are not the way they used to be, that we are moving from a "cost-based" to a "value-based" system. Steve discusses this paradigm shift in today's show and explains why we need new assumptions in the world of pharma and biotech.

Early in the interview, Steve previews the first Burrill and Buck Aging Conference coming up May 20-21 in Novato California. The interview ends with Burrill's thoughts on the Myriad gene patent case.

Eric Topol and His "Creative Destruction"

Podcast brought to you by: The Burrill and Buck Aging Conference Explore how innovative approaches from regenerative medicine to digital health stand to change our notion of what it means to grow old.

Guests:

Eric Topol, MD, Cardiologist, Genetic Researcher, and Technologist Bio and Contact Info

Listen (6:22) Patient stories heard at Future of Genomic Medicine Conference

Listen (4:34) Medical community's response to book

Listen (6:02) "I just wish I could go back and start medical school again"

Listen (4:30) Eradicate fee for service

Listen (3:05) Craig Venter: Quality of sequencing has gone down

Listen (4:29) "De"personalized medicine?

Listen (0:58) Excited about rollout of sensors

Eric Topol joins us to discuss what was perhaps the most talked about book in the life sciences in 2012, his "The Creative Destruction of Medicine." In his book, Topol tells of the now arriving era of individualized medicine and the rise of "homo digitus," or digital man. In today's show, Topol dives into some key topics from the book such as how to deal with misaligned incentives in healthcare. "I just wish I could go back and start medical school again because this is truly an era . . a renaissance, an enlightenment in the medical space," says Topol when asked about what he advises young people.

Dr. Topol recently hosted the Future of Genomic Medicine Conference at The Scripps in San Diego, and he begins the interview giving some highlights of patient stories.

FDA Clearance Sends dHealth Pioneer Into Overdrive: Dr Dave, AliveCor

Podcast sponsored by: "Your Organization Name Here" - Build your brand at Mendelspod. Click here for details.

Guest:

Dr. Dave Albert, Founder, AliveCor Bio and Contact Info

Listen (8:43) Device cleared for medical community, not yet OTC

Listen (6:24) If I could, should I buy this device?

Listen (5:14) Fusing consumer health with traditional med device

Listen (5:09) Was this clearance a new exercise for the FDA?

Listen (4:40) How will you get around misaligned incentives for physicians?

Listen (1:49) Are there any downsides to piggy-backing on a smart phone?

Over the past year we've been closely following AliveCor, the new digital health pioneer. Cardiologist, David Albert, came up with a simple device that fits on the iPhone and can immediately give a person a readout of their ECG. His company, AliveCor, has generated a fair amount of buzz, not least of which is the notice they get from Steve Burrill in many of his talks. It's become a part of Steve's spiel about how healthcare is changing. Steve will stop, pull out his iPhone, put it on his chest and then watch the audience ooh and ah. The company has a stellar lineup of supporters/advisors. I mentioned Steve Burrill, who is an investor. Eric Topol, author of The Creative Destruction of Medicine, is a big fan.

Last week the company received the coveted FDA clearance to sell the device into the medical community. They'll now pursue an OTC clearance so that you and I could buy one for those scary days after a relationship break up or an earthquake and check our own heart stats. Is this company, a fusion of the new consumer health movement and traditional med device, an example of many companies to come? Dr Dave joins us to answer this question and others.

Commercializing Research: U of I Research Park

Podcast Sponsor: Ingenuity - iReport, the fastest and most accurate way to get biological meaning from your expression data. www.ingenuity.com/get iReport/

Guests:

Laura Frerichs, Director, University of Illinois Research Park Bio and Contact Info

Yi Lu, PhD ,Professor, University of Illinois Bio and Contact Info

Listen (3:49) What is the process for turning research into a successful startup?

Listen (10:53) Advantages to using the U of I Research Park

Listen (2:45) Trend is toward commercializing more research

Listen (1:46) Are there conflicts of interest here?

Listen (5:59) Dr. Lu is the founder of two companies at U of I Research Park

Listen (3:32) Decision to start a company

Listen (7:18) Leveraging existing glycometers to look for biomarkers

Listen (4:37) Does commercialization detract from research?

Listen (4:52) Why he's excited about digital health

Recently we’ve had on several guests who have created start-ups from technology developed at Stanford University. Today we have two guests on the program to talk about commercializing technologies developed at universities.

Laura Frerichs is the Director of the Research Park and Incubation Facilities at the University of Illinois. Laura discusses the programs that the Research Park has put in place to assist young businesses.

Later we talk with Dr. Yi Lu, a professor at the University of Illinois and founder of two start-ups, one of which has graduated from the Incubator.

Consumers, Not Patients: Don Jones, Qualcomm Life

Podcast Sponsor: Ingenuity - iReport, the fastest and most accurate way to get biological meaning from your expression data. www.ingenuity.com/get iReport/

Guest:

Don Jones, Vice President, Global Strategy and Market Development Qualcomm Life Bio and Contact Info

Listen (3:14) Why talk to Qualcomm on a life science media site?

Listen (2:32) What apps most excite you?

Listen (2:33) Consumers rather than patients

Listen (5:07) Qualcomm employee programs

Listen (5:44) Wireless can help us change our habits

Listen (1:34) Qualcomm as investor

Listen (1:54) The FDA challenge

Listen (3:45) Personal journey to wireless health

Listen (4:28) How do you currently interact with your doctor?

Every time you make a call on your cell phone, you’re using technology from Qualcomm. Now the chip maker is getting involved in healthcare. Don Jones, VP of global strategy and market development in wireless health, at Qualcomm is on a mission to bring wireless technologies to health and life sciences markets.

Jones was a founding board member of the West Wireless Health Institute, with Eric Topol and Gary and Mary West. It’s the world’s first and foremost Institute focused on the clinical efficacy and economic efficiencies of wireless technologies in healthcare. He founded Wireless Life Sciences Alliance, a local trade group based in San Diego.

Don shares his vision for where health is going in a world where more people have cell phones than have access to clean drinking water.

Innovating in the New Austerity: Steve Burrill Discusses His Book

Podcast brought to you by: Assay Depot - the world's largest cloud-based marketplace for research services. With Assay Depot, you can easily find the perfect research service provider and manage your project from anywhere in the world.

Guest:

Steve Burrill, CEO, Burrill and Co. Bio and Contact Info

Chapters (Move marker to advance)

0:58 Is there a connection between innovation and austerity?

8:58 Consequences of the world's aging population

13:57 Ramifications of upcoming Supreme Court decision on Affordable Care Act

17:41 Opportunities abroad

25:40 Challenges abroad

31:21 AliveCor and Digital Health

39:03 A biologic on track to be world's top selling drug

Today we’re at the offices of Burrill and Co with CEO, Steve Burrill. Steve hardly needs an introduction in our industry. He was an early pioneer of biotech and helped set up such companies as Genentech and Cetus. Each year Burrill and Co. publishes a book on the state of the industry. It’s a complete almanac of information from what’s going on in such places as Singapore and Brazil to the digital health boom happening right here at home. More importantly it’s not just information, but a comprehensive guide to the industry and full of insight. Steve is more comfortable talking about the future than anyone I know. Today he challenges us with the notion that innovation can come at a time of austerity, and downplays the ramifications of the upcoming Supreme Court decision on the Affordable Care Act of 2010. Burrill also discusses a company he's recently invested in and whose board he chairs, AliveCor and makes his own projections of the rapidly growing industry of digital health.

Support mendelspod.com by purchasing Steve's book, "Innovating in the New Austerity," here.



New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup